论文部分内容阅读
目的:观察重组人脑利钠肽联合连续性肾脏替代治疗心肾综合征难治性心力衰竭的临床疗效。方法:48例心肾综合征难治性心力衰竭患者随机分为观察组及对照组各24例。对照组给予常规药物治疗及连续性肾脏替代治疗,观察组在对照组基础上联合重组人脑利钠肽治疗。治疗7 d后对比两组患者血清N端B型尿钠肽前体(NT-Pro BNP)、心率、超声心动图左室射血分数(LVEF)、每搏输出量(SV)、血清尿素氮(BUN)、肌酐(Scr),肾小球滤过率(GFR)等指标,评价两组的临床疗效。结果:治疗后两组患者各项观察指标较治疗前均有明显改善(P<0.05),且观察组治疗后各指标均优于对照组(P<0.05)。观察组总有效率明显高于对照组(91.67%vs 79.17%,P<0.05)。结论:联合使用重组人脑利钠肽及连续性肾脏替代治疗能够更好的改善心肾综合征难治性心力衰竭患者的心肾功能,提高临床疗效。
Objective: To observe the clinical efficacy of recombinant human brain natriuretic peptide combined with continuous renal replacement therapy for refractory heart failure with cardiopulmonary syndrome. Methods: Forty-eight patients with heart-kidney syndrome-refractory heart failure were randomly divided into observation group (24 cases) and control group (24 cases). The control group was given conventional drug treatment and continuous renal replacement therapy. The observation group was treated with recombinant human brain natriuretic peptide on the basis of the control group. After 7 days of treatment, the levels of serum NT-ProBNP, heart rate, left ventricular ejection fraction (LVEF), stroke volume (SV), serum urea nitrogen (BUN), creatinine (Scr), glomerular filtration rate (GFR) and other indicators to evaluate the clinical efficacy of the two groups. Results: After treatment, the observation indexes in both groups were significantly improved (P <0.05), and the indexes in the observation group were better than those in the control group after treatment (P <0.05). The total effective rate in the observation group was significantly higher than that in the control group (91.67% vs 79.17%, P <0.05). Conclusion: Combined use of recombinant human brain natriuretic peptide and continuous renal replacement therapy can better improve the heart and kidney function of patients with refractory heart failure syndrome and improve the clinical curative effect.